Favipiravir (T-705) 100mg

Target: RNA-dependent RNA polymerase

Size: 100 mg

Chemical name: 6-fluoro-3-hydroxypyrazine-2-carboxamide

Formula: C5H4FN3O2

Molecular weight: 157.1

Purity: 99.95 % (HPLC)

Solubility: 31 mg/mL (DMSO), 20 mg/mL (ethanol), 12 mg/mL (water)

Storage: 3 years -20°C powder, 2 years -80°C in solvent

In vitro:
Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [2]

In vivo:
In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. [1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. [3]

References:
[1] Furuta Y, et al. Antimicrob Agents Chemother. 2002, 46(4), 977-981.
[2] Baranovich T, et al. J Virol. 2013, 87(7), 3741-3751.
[3] Madelain V, et al. Antiviral Res. 2015, 123, 70-77.

Favipiravir (T-705) has been referenced in publications:

Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro. [ Antiviral Res, 2019, 170:104570] PubMed: 31362004

Memory Impairment Induced by Borna Disease Virus 1 Infection is Associated with Reduced H3K9 Acetylation [Jie J, et al. Cell Physiol Biochem, 2018, 49(1):381-394] PubMed: 30138929

Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses [Tokunaga T, et al. Antiviral Res, 2017, 143:237-245] PubMed: 28465146

Favipiravir Datasheet

SDS_Favipiravir